ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1608

Vascular Effect of Treat to Target in Early Rheumatoid Arthritis Patients – A 5-year Prospective Study

Huan Meng1, Isaac Cheng2, Byran P Yan1, Alex PW Lee1, Ho So1 and Lai-shan Tam2, 1The Faculty of Medicine, CUHK, Hong Kong, Hong Kong, 2The Chinese University of Hong Kong, Hong Kong, China

Meeting: ACR Convergence 2022

Keywords: Disease Activity, Inflammation, rheumatoid arthritis, Subclinical Cardiovascular Disease

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: RA – Treatment II: Pre- and Early Disease

Session Type: Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis driven by chronic inflammation. We have previously reported that achieving sustained disease activity score 28 (DAS28) remission was associated with a significantly greater improvement in brachial-ankle pulse wave velocity (baPWV) in early RA (ERA) patients. This study was aimed to explore the long-term potential cardiovascular benefit of the well-recognized tight control treatment strategy in ERA. Whether treating to target over time is associated with long-term vascular outcomes in early RA (ERA) remained unclear.

Methods: This was a 5-year prospective study in patients with ERA. Consecutive ERA patients without overt cardiovascular disease were recruited. Patients received tight-control treatment in the first year, followed by standard-of-care management subsequently. Subclinical atherosclerosis was assessed using high-resolution carotid ultrasound (US) at baseline and year 5. The primary outcome was subclinical atherosclerosis progression (AP+), defined as incident plaque or an increased region harboring plaques, and/or maximum carotid intima-media thickness (max cIMT) progressed to over 0.9 mm at year 5. Disease activity score 28-erythrocyte sedimentation rate (DAS28-ESR) level was measured during each clinic visit. Cumulative averages of the area measured cumulative disease activity under the curve for DAS28-ESR (ca-DAS28-ESR) over a period of 5 years. Persistent LDA was defined as ca-DAS28-ESR ≤3.2.

Results: One-hundred and four ERA patients (age: 52±11 years, 81(78%) female) who completed five years of follow-up were included in this analysis (Table 1). There was marked improvement in disease activity after five years of treatment (DAS-ESR at baseline: 5.8±0.9 vs. 3.2±1.2 at year 5, p< 0.001) (Figure 1). Fifty (47%) patients achieved persistent LDA. Forty-two patients (40.4%) had AP+. Patient in the AP+ group were older, had higher Framingham risk scores (FRS) and had higher exposure to anti-hypertension drugs at baseline (Table 1). The use of medication throughout study period was similar across two groups. In multivariate logistic regression, moderate and high disease activity was an independent predictor with AP+ (OR=3.19, 95% CI: 1.11-9.22, p=0.032) after adjustment for Anti-CCP positive and Framingham risk score at baseline (Table 2).

Conclusion: Achieving persistent LDA was an independent predictor of subclinical atherosclerosis in ERA. Effective long-term suppression of disease activity is required to minimize cardiovascular risk.

Supporting image 1

Supporting image 2

Supporting image 3

Figure 1. Disease activity state according to DAS28-ESR across the study period. LDA: low disease activity.


Disclosures: H. Meng, None; I. Cheng, None; B. Yan, None; A. Lee, None; H. So, None; L. Tam, AbbVie, Amgen, Boehringer-Ingelheim, Eli Lilly, GlaxoSmithKlein(GSK), Janssen, Novartis, Pfizer, Sanofi, AstraZeneca.

To cite this abstract in AMA style:

Meng H, Cheng I, Yan B, Lee A, So H, Tam L. Vascular Effect of Treat to Target in Early Rheumatoid Arthritis Patients – A 5-year Prospective Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/vascular-effect-of-treat-to-target-in-early-rheumatoid-arthritis-patients-a-5-year-prospective-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vascular-effect-of-treat-to-target-in-early-rheumatoid-arthritis-patients-a-5-year-prospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology